2025 Simposio de la AF: Actualización del canal de desarrollo de medicamentos de AF (7)

Actualización del canal de desarrollo de medicamentos de AF y panel de preguntas y respuestas Moderado por Jennifer Farmer, directora ejecutiva de FARA Representantes de Biogen, Design Therapeutics, Larimar Therapeutics, Lexeo Therapeutics, PTC Therapeutics y Solid Biosciences Los servicios de interpretación en español son posibles gracias al apoyo de Biogen. Proporcionado por Equal Access Language Services, LLC. FARA's Mission is to marshal and focus the resources and relationships needed to cure Friedreich's Ataxia (FA) by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases. Friedreich’s Ataxia is a debilitating, life-shortening, degenerative neuro-muscular disorder. About one in 50,000 people in the United States have Friedreich's Ataxia. Subscribe to FARA's YouTube channel    / fara1998   Follow FARA on Facebook   / curefa   Follow FARA on Instagram   / curefa_org